Crossmark

ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial

Crossref DOI link: https://doi.org/10.1186/s12885-023-10632-9

Published Online: 2023-02-22

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kringelbach, Tina

Højgaard, Martin

Rohrberg, Kristoffer

Spanggaard, Iben

Laursen, Britt Elmedal

Ladekarl, Morten

Haslund, Charlotte Aaquist

Harsløf, Laurine

Belcaid, Laila

Gehl, Julie

Søndergaard, Lise

Eefsen, Rikke Løvendahl

Hansen, Karin Holmskov

Kodahl, Annette Raskov

Jensen, Lars Henrik

Holt, Marianne Ingerslev

Oellegaard, Trine Heide

Yde, Christina Westmose

Ahlborn, Lise Barlebo

Lassen, Ulrik
License Information

Text and Data Mining valid from 2023-02-22

Version of Record valid from 2023-02-22
More Information

Article History

Received: 22 December 2022

Accepted: 10 February 2023

First Online: 22 February 2023

Declarations

:

: The Protocol is approved by the Danish Ethics Committee (H-19089780; date of first approval: 19-JUN-2020) and is conducted in full conformance with the “Declaration of Helsinki” and the Danish laws and regulations. Written informed consent was obtained from all the patients.

: Not applicable.

: CAH: Within the last two years CAH has received honoraria for lectures from GSK and BMS.

Document is current

Any future updates will be listed below